PCM
IDXX icon

Prelude Capital Management’s Idexx Laboratories IDXX Stock Holding History

Prelude Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,000
Closed -$399K – 1747
2013
Q3 		$399K Buy
+8,000
New +$385K 0.06% 351

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's IDXX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Idexx Laboratories (IDXX) in Q1 2026: 595 shares worth $334K. The stake represents 0.03% of the portfolio and ranks #662 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in IDXX as recently as Q1 2025.

Prelude Capital Management first reported a position in IDXX in Q4 2014 and has held it in 25 quarters since. The position peaked at $1.61M in Q4 2022. 1,313 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Prelude Capital Management held 595 shares of Idexx Laboratories worth $334K as of Q1 2026.
  • Idexx Laboratories was a new Prelude Capital Management position in Q1 2026.
  • Idexx Laboratories made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #662 holding.
  • Prelude Capital Management first reported a position in Idexx Laboratories in Q4 2014 and has held it in 25 quarters since.
  • Prelude Capital Management's Idexx Laboratories position peaked at $1.61M in Q4 2022.
  • 1,313 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.